Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | QPCT | Q16769 | 1/20 | 0.46 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29715635 | 0.86 | MEN1 (1.00) | MEN1KMT2ASIGMAR1TAAR1IDO1 | |
| SCHEMBL1703266 | 0.86 | MEN1 (1.00) | MEN1KMT2ASIGMAR1TAAR1IDO1 | |
| SCHEMBL12479353 | 0.81 | MEN1 (0.64) | MEN1KMT2AHRH3HCRTR2 | |
| SCHEMBL12479925 | 0.79 | MAPT (0.50) | MEN1KMT2ATAAR1HCRTR2DAO | |
| SCHEMBL12479938 | 0.79 | ALDH1A1 (0.56) | MEN1KMT2ASIGMAR1TAAR1HRH3 | |
| SCHEMBL1703251 | 0.78 | MAPT (0.49) | MEN1KMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL3711080 | 0.76 | MAPT (0.49) | MEN1KMT2ASIGMAR1 | |
| SCHEMBL27874761 | 0.76 | SIGMAR1 (0.57) | MEN1KMT2ASIGMAR1TAAR1HRH3 | |
| SCHEMBL16612771 | 0.74 | ADRB2 (0.50) | MEN1KMT2AHCRTR2 | |
| SCHEMBL12479701 | 0.74 | ADRB2 (0.63) | MEN1KMT2AHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675801-B1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-08 | — | — | EP | claimed |
| EP-2675801-A1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-12-25 | — | — | EP | claimed |
| WO-2012110986-A1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-08-23 | — | — | WO | claimed |
| EP-2675801-B1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-08 | — | — | EP | disclosed |
| EP-2675801-A1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| WO-2012110986-A1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-08-23 | — | — | WO | disclosed |
| EP-2440548-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | Abbott Laboratories (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144468-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | MEN1 1727/4885KMT2A 849/4885SIGMAR1 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.